3SBioSTU:83B +11.72%90 Interest Coverage is 398.23 as of Dec. 2025, which is 2949% above its 10-year median of 13.06. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.57 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 377 Biotechnology companies, 3SBio ranks better than 51.19% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. 3SBio's
Operating Income
for the
six
months ended in Dec. 2025 was €1,129 Mil. 3SBio's Interest Expense for the
six
months ended in Dec. 2025 was €-3 Mil.
3SBio's interest coverage for the quarter that ended in Dec. 2025 was 398.23.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. 3SBio Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for 3SBio's Interest Coverage or its related term are showing as below:
STU:83B'
s Interest Coverage Range Over the Past 10 Years
Min: 6.2 Med: 13.06 Max: 139.85
Current: 139.85
STU:83B's Interest Coverage is ranked better than 51.19% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs STU:83B: 139.85
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
3SBio Interest Coverage Related Terms
3SBio Interest Coverage Historical Data
* Premium members only.
The historical data trend for 3SBio's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
STU:83B vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, 3SBio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's Interest Coverage distribution charts can be found below:
* The bar in red indicates where 3SBio's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (STU:83B) has a Interest Coverage of 398.23 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on 3SBio and its competitors. This is 2949% above median its historical median of 13.06. Over the past decade, 3SBio's Interest Coverage has ranged from 6.20 to 139.85. According to the industry distribution chart, 3SBio ranks #184 out of 377 companies in the Biotechnology industry, placing it in the top 48.8%.
Is 3SBio's Interest Coverage too high?
3SBio's current Interest Coverage of 398.23 is 2949% above median its 10-year median of 13.06. Over the past 10 years, this metric has ranged from a low of 6.20 to a high of 139.85. The Biotechnology industry median Interest Coverage is 106.07. 3SBio's value of 398.23 is 275.4% above this industry median. Based on the distribution chart, 3SBio ranks #184 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #184 out of 377 companies for Interest Coverage. This puts 3SBio in the upper half of its industry. The industry median Interest Coverage is 106.07. 3SBio's value of 398.23 is 275.4% above this benchmark. Historically, 3SBio's own Interest Coverage has ranged from 6.20 to 139.85 over the past decade. While the company's 10-year median is 13.06 vs. the industry median of 106.07, 3SBio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3SBio's current Interest Coverage of 398.23 is 275.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on 3SBio and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3SBio's current Interest Coverage is 398.23, which is 2949% above median its own 10-year median of 13.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.57, compared to a current price of €1.90 — trading 21.3% above its estimated fair value. The current Interest Coverage is 398.23, which is 2949% above median its 10-year median of 13.06 and 275.4% above the Biotechnology industry median of 106.07. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For 3SBio (STU:83B), the current Interest Coverage is 398.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.90 is trading 21.3% above its estimated GF Value™ of €1.57.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
Interest Coverage: 398.23 (2949% above median its 10-year median of 13.06)
GF Value™: €1.57 vs. price of €1.90 (21.3% above fair value)
Industry Position: 275.4% above the Biotechnology median (#184 of 377)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for STU:83B
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
